{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-37","spread":"-37","upperLimit":"66","value":"22"},{"groupId":"OG001","lowerLimit":"-36","spread":"-36","upperLimit":"-36","value":"-36"},{"groupId":"OG002","lowerLimit":"-37","spread":"-37","upperLimit":"24","value":"-19"},{"groupId":"OG003","lowerLimit":"-30","spread":"-30","upperLimit":"-30","value":"-30"},{"groupId":"OG004","lowerLimit":"-43","spread":"-43","upperLimit":"12","value":"-21"},{"groupId":"OG006","lowerLimit":"-17","spread":"-17","upperLimit":"6","value":"-15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"Tumor tissue biopsies were performed at Baseline and on Day 15 3 hours post dose. Levels of pS6RP were quantified using immunohistochemical (IHC) methods.","dispersionType":"Full Range","groups":[{"description":"Participants with NSCLC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part B: Non-small Cell Lung Cancer (NSCLC)"},{"description":"Participants with GBM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part B: Glioblastoma Multiforme (GBM)"},{"description":"Participants with HCC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part B: Hepatocellular Carcinoma (HCC)"},{"description":"Participants with NET received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part B: Neuroendocrine Tumor (NET)"},{"description":"Participants with DLBCL received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part B: Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with MM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG005","title":"Part B: Multiple Myeloma (MM)"},{"description":"Participants with HRPBC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG006","title":"Part B: Hormone Receptor Positive Breast Cancer (HRPBC)"}],"paramType":"MEDIAN","populationDescription":"All biomarker evaluable participants who received treatment in Part B.","reportingStatus":"POSTED","timeFrame":"Up to Cycle 1 Day 15 3 hours post dose","title":"Part B: Percent Change From Baseline in pS6RP Levels in Tumor Tissue by Tumor Type","type":"SECONDARY","unitOfMeasure":"Percent change in pS6RP"}